



CAMFiC AL DIA
L'actualització en AP



CAMFiC
societat catalana de medicina
familiar i comunitària

QUIN ÉS L'IMPACTE DELS FACTORS DE RISC MODIFICABLES EN LA MALALTIA CARDIOVASCULAR I MORT ASSOCIADA?

Dra. Laura Oromí

Metgessa de Família. CAP Comte Borrell
Grup de Treball Lípids de la CAMFiC

SENSE CONFLICTES D'INTERÈS




INDEX

1. MALALTIA CARDIOVASCULAR
2. FACTORS DE RISC CARDIOVASCULAR
3. RISC RESIDUAL
4. ALTRES FACTORS DE RISC
5. CONCLUSIONS



- Malaltia més **prevalent**
- Representa 1/3 de totes **les morts** a nivell mundial
- **Cardiopatia isquèmica** és la principal causa de morbimortalitat a nivell mundial
- Quins factors intervenen en el seu **origen i desenvolupament?**



- ▶ Infarto de miocardi
- ▶ Cardiopatia isquèmica
- ▶ Insuficiència cardíaca
- ▶ Muerte súbita
- ▶ Cardiopaties familiars y genética
- ▶ Valvulopatías
- ▶ Arritmias
- ▶ Fibrilación auricular
- ▶ Cardiopaties congénitas
- ▶ Síndrome de Tako-Tsubo
- ▶ Tromboembolismo pulmonar
- ▶ Enfermedad de Kawasaki
- ▶ Coartación de aorta
- ▶ Foramen oval permeable
- ▶ Síndrome de Brugada
- ▶ Síndrome de Marfan
- ▶ Ductus arterioso
- ▶ Transposició de grandes vasos

N Engl J Med . 2023 October 05; 389(14): 1273–1285.



- Factors no modificables
- Factors modificables
 - **Diabetis**
 - **Hipertensió**
 - Alteració del perfil lipídic
 - **Obesitat**, sedentarisme
 - **Tabac**
 - **Alimentació**
 - Factors psicosocials
 - ...

Epidemiological Approaches to Heart Disease: **The Framingham Study***

THOMAS R. DAWBER, M.D., GILCIN F. MEADORS, M.D.,
M.P.H., AND FELIX E. MOORE, JR.

*National Heart Institute, National Institutes of Health, Public Health Service,
Federal Security Agency, Washington, D. C.*

1948 – ACTUALITAT

ESTUDI DE COHORTS

3ª GENERACIÓ DE PARTICIPANTS

ESTUDI MÉS IMPORTANT ORIGEN
DEL QUE SABEM AVUI EN DIA

Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study

Salim Yusuf, Steven Hawken, Stephanie Ôunpuu, Tony Dans, Alvaro Avezum, Fernando Lanas, Matthew McQueen, Andrzej Budaj, Prem Pais, John Varigos, Liu Lisheng, on behalf of the INTERHEART Study Investigators*




Figure 4: Association of risk factors with acute myocardial infarction in men and women after adjustment for age, sex, and geographic region


For this and subsequent figures, the odds ratios are plotted on a doubling scale. Prevalence cannot be calculated for psychosocial factors because it is derived from a model.

$p < 0.0001$ for all risk factors and $p = 0.03$ for alcohol

CASOS I CONTROLS
 - 15.152 CASOS AMB IAM
 - 14.820 CONTROLS SANS
 52 països

Aquests 9 FACTORS van suposar el 90% del risc poblacional atribuïble en els homes i el 94% en les dones.

Yusuf S, et al. Lancet. 2004;364:937-52.



HHS Public Access

Author manuscript

N Engl J Med. Author manuscript; available in PMC 2023 October 21.

Published in final edited form as:

N Engl J Med. 2023 October 05; 389(14): 1273–1285. doi:10.1056/NEJMoa2206916.

Global Impact of Modifiable Risk Factors on Cardiovascular Disease and Mortality

REVISIÓ DE 112 ESTUDIS DE COHORTS 34 països

Estudi de 5 FRCV modificables
IMC, TAS, no-cHDL, DM, Tabac

Incidència MCV
- 57,2% en dones
- 52,6% en homes

Morts
- 22,2% en dones
- 19,1% en homes

Figure 3. Population-attributable fractions of risk factors for 10-year cardiovascular disease and all-cause mortality. Models were computed using a one-year landmark analysis. (A) Aggregate global population-attributable fractions. (B) Population-attributable fractions for aggregate risk factors by geographic region. (C) Population-attributable fractions for single risk factors in direct regional comparison.



A DIA D'AVUI

- **Cardiopatia isquèmica segueix essent** la principal causa de morbimortalitat a nivell mundial.

Hi ha altres factors contribuents ?

Mortality in STEMI patients without standard modifiable risk factors: a sex-disaggregated analysis of SWEDEHEART registry data

Gemma A Figtree, Stephen T Vernon, Nermin Hadziosmanovic, Johan Sundström, Joakim Alfredsson, Clare Arnott, Vincent Delatour, Margrét Leósdóttir, Emil Hagström

2021



ESTUDI RETROSPECTIU


62.048 pacients amb un primer esdeveniment de IAMEST.

El 15% en absència de FRCV modificables tenien un risc augmentat de mortalitat per totes les causes.


Hi ha altres **etiologies no conegudes** que predisposen a presentar Cardiopatia isquèmica ?

1. Figtree GA et al Mortality in STEMI patients without standard modifiable risk factors: a sex-disaggregated analysis of SWEDEHEART registry data. Lancet. 2021 Mar 20;397(10279):1085-1094.
 2. European Heart Journal (2024) 45, 419–438






El **RCV residual** és aquell que **persisteix** malgrat els estàndards actuals de tractament i assolir els **objectius de cLDL, PA i HbA1c**




Patel KV, et al. Circulation. 2018;137:2551-3.



1. Modificada de :Ginsberg HN et al.. Eur Heart J. 2021;42:4791---806,<http://dx.doi.org/10.1093/eurheartj/ehab551.16>
2. Pintó X, Fanlo M et al. Clinica e Investigacion en Arteriosclerosis 35 (2023) 206---217.

INCIDENCIA DE ECV SEGÚN LAS CATEGORÍAS PREDEFINIDAS DE C-LDL Y COLESTEROL REMANENTE
 Estudio Predimed



C-LDL \leq 100 mg/dL y C-Remanente $>$ 30 mg/dL

C-LDL $>$ 100 mg/dL y C-Remanente $>$ 30 mg/dL


C-LDL $>$ 100 mg/dL y C-Remanente \leq 30 mg/dL

C-LDL \leq 100 mg/dL y C-Remanente \leq 30 mg/dL

Remnant-C & LDL-C Groups	HR (95% CI), p value
LDL-C \leq 100 mg/dL (2.56 mmol/L) and Remnant-C \leq 30 mg/dl (0.77 mmol/L) n = 880 (12.7%)	Reference
LDL-C \leq 100 mg/dL (2.56 mmol/L) and Remnant-C $>$ 30 mg/dl (0.77 mmol/L) n = 400 (5.8%)	2.69 (1.52, 4.75) p = 0.001
LDL-C $>$ 100 mg/dL (2.56 mmol/L) and Remnant-C \leq 30 mg/dl (0.77 mmol/L) n = 4,124 (59.8%)	1.36 (0.85, 2.16) p = 0.195
LDL-C $>$ 100 mg/dL (2.56 mmol/L) and Remnant-C $>$ 30 mg/dl (0.77 mmol/L) n = 1,497 (21.7%)	1.89 (1.16, 3.08) p = 0.011

1. Quispe R, et al. Eur Heart J.2021;42:4324---32.215

2. Pintó X, Fanlo M et al. Clinica e Investigacion en Arteriosclerosis 35 (2023) 206---217.



Exposome in ischaemic heart disease: beyond traditional risk factors


Rocco A. Montone ^{1*}†, **Massimiliano Camilli** ^{1,2†}, **Camilla Calvieri**³,
Giulia Magnani ⁴, **Alice Bonanni** ¹, **Deepak L. Bhatt** ⁵, **Sanjay Rajagopalan**⁶,
Filippo Crea^{1,2}, and **Giampaolo Niccoli**⁴

¹Department of Cardiovascular Medicine, Fondazione Policlinico Universitario A. Gemelli IRCCS, L.go A. Gemelli, 1, 00168 Rome, Italy; ²Department of Cardiovascular and Pulmonary Sciences, Catholic University of the Sacred Heart, Rome, Italy; ³Sapienza University, Rome, Italy; ⁴Department of Medicine, University of Parma, Parma, Italy; ⁵Mount Sinai Heart, Icahn School of Medicine at Mount Sinai, New York, NY, USA; and ⁶Cardiovascular Research Institute, Case Western Reserve University, Cleveland, OH 44106, USA

Received 8 June 2023; revised 22 December 2023; accepted 3 January 2024; online publish-ahead-of-print 18 January 2024

Patel KV, et al. CirculaKon. 2018;137:2551-3.

The exposome beyond traditional cardiovascular risk factors


Exposome in ischaemic heart disease: beyond traditional risk factors

Rocco A. Montone ^{1*}**†**, **Massimiliano Camilli** ^{1,2†}, **Camilla Calvieri**³, **Giulia Magnani** ⁴, **Alice Bonanni** ¹, **Deepak L. Bhatt** ⁵, **Sanjay Rajagopalan**⁶, **Filippo Crea**^{1,2}, and **Giampaolo Niccoli**⁴

¹Department of Cardiovascular Medicine, Fondazione Policlinico Universitario A. Gemelli IRCCS, Lgo A. Gemelli, 1, 00168 Rome, Italy; ²Department of Cardiovascular and Pulmonary Sciences, Catholic University of the Sacred Heart, Rome, Italy; ³Sapienza University, Rome, Italy; ⁴Department of Medicine, University of Parma, Parma, Italy; ⁵Mount Sinai Heart, Icahn School of Medicine at Mount Sinai, New York, NY, USA; and ⁶Cardiovascular Research Institute, Case Western Reserve University, Cleveland, OH 44106, USA

Received 8 June 2023; revised 22 December 2023; accepted 3 January 2024; online publish-ahead-of-print 18 January 2024

Major non-traditional risk factors for ischaemic heart disease, including environmental pollution, mental health disorders, and infectious diseases, SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

European Heart Journal
(2024) 45, 419–438

The exposome beyond traditional cardiovascular risk factors


Estrès oxidatiu, Inflamació

Resposta trombòtica

Resistència a la insulina

Augment de la tensió arterial

Disfunció endotelial i agregació plaquetària




Major non-traditional risk factors for ischaemic heart disease, including environmental pollution, mental health disorders, and infectious diseases, SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

European Heart Journal
(2024) 45, 419–438

RISC RESIDUAL – ALTRES FACTORS DE RISC

The exposome beyond traditional cardiovascular risk factors




Activació SNS augmenta la pressió arterial

Augment de la grassa visceral

Resistència a la insulina

Major non-traditional risk factors for cardiovascular disease include air pollution, infectious diseases, SARS-CoV-2, severe acute respiratory syndrome coronavirus 2, on, mental health disorders, and

European Heart Journal
(2024) 45, 419–438



Major non-traditional risk factors for ischaemic heart disease, including environmental pollution, mental health disorders, and infectious diseases, SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

European Heart Journal
(2024) 45, 419–438

The exposome beyond traditional cardiovascular risk factors

Estrès oxidatiu, Inflamació

Estrès oxidatiu


Resposta trombòtica

Resistència a la insulina

Augment de la tensió arterial

Disfunció endotelial i agregació plaquetària

Activació SNS augmenta la pressió arterial



Augment de la permeabilitat intestinal i endotoxèmia de baix grau

Trombosi i ruptura de la placa

Augment de la grassa visceral

Resistència a la insulina

Major non-traditional risk factors for ischaemic heart disease, including environmental pollution, mental health disorders, and infectious diseases, SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

European Heart Journal
(2024) 45, 419–438




Figure 1 Impact of traditional and non-traditional risk factors on overall death, and death from ischaemic heart disease and DALYs. Data from the GBD 2019 reports³³

Morts totals i anys de vida ajustats per discapacitat

1. La malaltia cardiovascular és **molt prevalent**.
2. La **cardiopatia isquèmica** continua essent la primera causa de morbimortalitat en l'actualitat.
3. Els **factors de risc** avaluats es mantenen **constants** en els diferents països.
4. El **risc residual** en la malaltia cardiovascular juga un **paper important**.
5. Cal abordar **altres factors** per tal de reduir la incidència de la malaltia cardiovascular.
6. La **contaminació de l'aire** ambiental s'ha convertit en la **principal causa ambiental de malalties i mort prematura arreu del món**, fins i tot en comparació amb altres factors de risc cardiovascular tradicionals.
7. Tot i ser conscients del canvi, **encara queda molt camí** per recórrer per implementar estratègies preventives i de gestió.



CAMFiC AL DIA

L'actualització en AP



CAMFiC
societat catalana de medicina
familiar i comunitària

